Compare ReproCELL, Inc. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROE of 0.31%
- The company has been able to generate a Return on Equity (avg) of 0.31% signifying low profitability per unit of shareholders funds
2
The company has declared negative results in Jan 70 after 2 consecutive negative quarters
3
Risky -
4
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 16,211 Million (Small Cap)
160.00
NA
0.00%
-0.66
-3.21%
1.87
Revenue and Profits:
Net Sales:
476 Million
(Quarterly Results - Jun 2025)
Net Profit:
-304 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.79%
0%
-4.79%
6 Months
47.22%
0%
47.22%
1 Year
16.06%
0%
16.06%
2 Years
-47.35%
0%
-47.35%
3 Years
-26.05%
0%
-26.05%
4 Years
-55.08%
0%
-55.08%
5 Years
-68.51%
0%
-68.51%
ReproCELL, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
19.94%
EBIT Growth (5y)
13.17%
EBIT to Interest (avg)
-518.22
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.44
Sales to Capital Employed (avg)
0.32
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0.31%
Valuation key factors
Factor
Value
P/E Ratio
160
Industry P/E
Price to Book Value
1.84
EV to EBIT
-96.27
EV to EBITDA
-157.51
EV to Capital Employed
2.49
EV to Sales
4.21
PEG Ratio
0.81
Dividend Yield
NA
ROCE (Latest)
-2.59%
ROE (Latest)
1.15%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
475.80
619.80
-23.23%
Operating Profit (PBDIT) excl Other Income
-274.50
-101.50
-170.44%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-304.30
-75.30
-304.12%
Operating Profit Margin (Excl OI)
-611.70%
-186.80%
-42.49%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -23.23% vs 11.39% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -304.12% vs -204.44% in Jun 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
2,978.60
2,426.80
22.74%
Operating Profit (PBDIT) excl Other Income
-79.70
-372.20
78.59%
Interest
0.00
0.00
Exceptional Items
0.00
-63.70
100.00%
Consolidate Net Profit
103.20
-31.40
428.66%
Operating Profit Margin (Excl OI)
-43.80%
-168.70%
12.49%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 22.74% vs -17.83% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 428.66% vs 89.72% in Mar 2024
About ReproCELL, Inc. 
ReproCELL, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






